HER-2/neu Assessment for Gastric Carcinoma: Validation of Scoring System

Mrklić, Ivana; Bendic, Antonia; Kunac, Nenad; Bežić, Joško; Forempoher, Gea; Durdov, Merica Glavina; Karaman, Ivana; Prusac, Ivana Kuzmić; Pisac, Valdi Pešutić; Vilović, Katarina; Tomić, Snježana

doi:10.5754/hge10776

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastric cancer is the most common gastric malignant tumor and the second leading cause of death due to cancer worldwide [1, 2]. Although it is a consensus that depth of tumor invasion and number of lymph node metastasis are most intensive factors to evaluate the progression and prognosis of gastric cancer, researchers demonstrated that tumor-node-metastasis (TNM) classification was imprecise for prediction the survival of patients even in the latest version [3].…”

Section: Introductionmentioning

confidence: 99%

Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer

et al. 2014

View full text Add to dashboard Cite

RNF 180, a novel tumor suppressor, has been implicated in the carcinogenesis and progress of gastric cancer. At present study, we found that lower expression of RNA180 was specific in gastric cancer tissues, and the inconsistently methylated levels of RNF180 promoter were identified in the gastric cancer tissues. Importantly, we demonstrated that the methylated CpG site count and four hypermethylated CpG sites (−116, −80, +97, and +102) were significantly associated with the survival of 400 gastric cancer patients, respectively. With multivariate survival analyses, we demonstrated that both the methylation of combined CpG (−116, −80, +97, and +102) sites and N stage were the independent indictor of prognosis of gastric cancer patients. Eventually, the methylation of combined CpG (-116, -80, +97, and +102) sites was identified to have smaller AIC value than N stage by mean of AIC calculation with the Cox proportional hazards model. These findings indicated that the quantitative detection of RNF180 promoter methylation had the intensive feasibility for evaluation the prognosis of gastric cancer patients in clinic.

show abstract

Section: Introductionmentioning

confidence: 99%

Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In our study, only HER2 IHC 2+ or IHC 3+ were considered HER2 positive. 6 In light of the WHO's classification of digestive tumors and UICC 2010 TNM classification of malignant tumors, 20,21 the pathologist reviewed and recorded a set of histopathological parameters as follows: (1) HER2 expression status, (2) location of tumor, (3) maximum diameter of tumor, (4) differentiation degree, (5) T stage (depth of infiltration), (6) N stage (lymph node metastasis), (7) M stage (distant metastasis), (8) vascular invasion status, and (9) neural invasion status.…”

Section: Pathological Evaluationmentioning

confidence: 99%

“…4,5 In 6-35% of all GC patients, gastric lesions have been reported to over-express HER2. [6][7][8][9][10] The status of HER2 expression in gastric lesions is currently evaluated by immunohistochemistry (IHC), silver in situ hybridization (SISH), and fluorescence in situ hybridization (FISH). 5,11,12 It was found to be correlated with tumor grade and location on the intestine, but not with gender, age, tumor location or (tumor node metastasis) TNM stage, depth of invasion, lymph node metastases, and distant metastasis.…”

Section: Introductionmentioning

confidence: 99%

<p>Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status?</p>

Wang¹,

Wang²,

Li³

et al. 2020

CMAR

View full text Add to dashboard Cite

These authors contributed equally to this workObjective: The aim of this study was to determine the role of contrast-enhanced computed tomography (CE-CT) parameters in predicting the expression status of HER2 in gastric adenocarcinoma (GAC) patients before radical gastrectomy. Materials and Methods: A total of 460 GAC patients who underwent non-contrast CT (NC-CT) and CE-CT examinations before radical resection were enrolled in this retrospective study. The radiologists reviewed their CT scans and recorded parameters, including CT attenuate value (CAV) and corrected CAV (cCAV). The pathologist identified the postoperative HER2 expression status, and HER2 expression status was evaluated by immunohistochemical staining (IHC). The association between CE-CT parameters and HER2 expression status was analyzed. Results: Among the 460 patients, 84 patients had HER2 over-expression status, at a prevalence of 18.3%. The CAVs were significantly different between the 2 different HER2 expression groups in the non-contrast and arterial phases (non-contrast phase: p = 0.005; arterial phase: p < 0.001). Besides, there was a significant difference in the cCAVs between the 2 groups in the arterial phase (arterial phase: p = 0.003). Univariate and multivariate logistic regression analyses identified that the maximum diameter of tumor, differentiation degree, CAV in non-contrast, arterial, and portal phases, and cCAV in the arterial phase were predictive factors of HER2 expression status. Conclusion: Our analyses showed that the CE-CT parameters were significantly different between different HER2 expression groups. CE-CT parameters could serve as simple, objective predictive factors of HER2 expression status of GAC patients.

show abstract

“…This scoring system is based on the intensity of reactivity, whether complete or incomplete and the percentage of reactive cells. 11,12 IHC score of 0 and 1+ was considered negative, while an IHC score of 2+ and 3+ was considered positive (Table 1). 11,13,14 Tumor cell clusters with strong complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained.…”

Section: Exclusion Criteriamentioning

confidence: 99%

HER2/neu immunohistochemical expression in gastric carcinoma

Sadanandan¹,

Arunraj²

2020

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Gastric carcinoma is a deadly disease with high mortality. A better understanding of the molecular basis of gastric cancer has contributed to the development of rationally designed molecular targeted therapies which will improve the survival rate. A genetic alteration that could help in targeted therapy and prognostication includes Human Epidermal Growth Factor Receptor 2 (HER2/neu) overexpression in gastric carcinoma. The objective of the present study was to identify and evaluate the HER2/neu protein immunohistochemical expression in gastric cancer from biopsies and surgical resection specimens and to evaluate their correlation with histopathological features.Methods: Total/subtotal gastrectomy specimens and gastric biopsies from a tertiary care center in South India were included in the study and assessed by light microscopy and Immunohistochemistry (IHC).Results: HER2/neu overexpression was seen in 28.6% of gastric adenocarcinoma. HER2/neu overexpression was seen in 44.2% of intestinal-type and 20% of mixed type with none of the diffuse type exhibited HER2/neu positivity and this was statistically highly significant with p value of <0.01. HER2/neu positivity was found in 50% well-differentiated and 36.4% moderately differentiated tumors with none of the poorly differentiated tumors exhibiting HER2/neu positivity and this was statistically highly significant with p value of <0.01.Conclusions: This study highlights the importance of the identification of HER2/neu overexpression in gastric adenocarcinoma. This will help in prognostication and identifying patients suitable for novel therapeutic interventions which will help in prolongation of survival of patients with this deadly disease.

show abstract

HER-2/neu Assessment for Gastric Carcinoma: Validation of Scoring System

Abstract: According to high concordance rate in paired samples we consider it appropriate to evaluate HER2 expression on biopsy specimens, especially in unresectable cases, and to re-evaluate it on resected specimens if available, due to high heterogeneity of a gastric cancer.

Cited by 6 publications

References 0 publications

Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer

Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer

<p>Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status?</p>

HER2/neu immunohistochemical expression in gastric carcinoma

Contact Info

Product

Resources

About